Back to Newsroom

Reuters: Pharnext drug shows promise in neurological disease with no treatment

(Reuters) – Using technology gleaned from the mapping of the human genome, privately held French drug developer Pharnext SAS is a step closer to providing a treatment for a rare neurological disorder called Charcot-Marie-Tooth (CMT) disease, for which no pharmaceutical therapy exists.

Click here to read more